Clinical Trial Update: Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating regorafenib plus temozolomide with or without radiotherapy in MGMT-methylated, IDH-wildtype glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Idh-wildtype
• Mgmt-methylated Glioblastoma

Drugs mentioned

• Regorafenib (regorafenib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Istituto Oncologico Veneto IRCCS | Conditions: Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma | Phase 1 | Status: COMPLETED